Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

RenovaCare Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
3335
Market Cap
0.01M

Momentum Score

…

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

RenovaCare Inc operates in regenerative medicine and wound care and develops a device-based autologous cell delivery technology intended to treat burns and chronic wounds. Major long-term growth drivers may include wider clinical adoption of cell-based wound therapies, an aging population with rising chronic wound incidence, and successful regulatory progress; investors may find exposure to a niche medical-technology approach worthwhile although public disclosure is limited.
Material investment risks include clinical and regulatory uncertainty, lack of established commercial revenue, frequent need for additional financing, and low liquidity associated with OTC Pink listing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-568.90%
Net Debt
-2.82M
ROCE
-230.49%
Diluted EPS TTM
-0.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - -4.47M -9.55M -3.36M -2.12M
Minority interest - - - - 0.00M
Net income - -4.47M -9.42M -3.36M -2.12M
Selling general administrative - 2.20M 5.54M 2.94M 1.64M
Gross profit - - - - 0.00M
Reconciled depreciation - 0.01M 0.02M 0.00M 0.00M
Ebit - -5.41M -9.68M -3.69M -1.99M
Ebitda - -5.40M -9.66M -3.36M -1.99M
Depreciation and amortization 0.23M 0.01M 0.02M 0.33M 0.00M
Non operating income net other - - - - 0.00M
Operating income - -5.41M -9.68M -3.69M -2.01M
Other operating expenses - 5.41M 9.68M 3.69M 2.01M
Interest expense - 0.01M 0.13M 0.33M 0.14M
Interest income - 0.01M 0.13M 0.33M 0.02M
Net interest income - 0.01M 0.13M 0.33M -0.11M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense - -0.01M -0.13M -0.33M 0.02M
Total revenue - 0.00M 0.00M 0.00M 0.00M
Total operating expenses - 5.41M 9.68M 3.69M 2.01M
Cost of revenue - - - - 0.00M
Total other income expense net - 0.94M 0.13M 0.33M -0.06M
Discontinued operations - - - - 0.00M
Net income from continuing ops - -4.47M -9.55M -3.36M -2.12M
Net income applicable to common shares - -4.47M -9.55M -3.36M -2.12M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - 3.65M 8.40M 12.44M 15.72M
Intangible assets - 0.15M 152854.00M 0.15M 152854.00M
Other current assets - 0.53M 566275.00M 102500.00M 0.17M
Total liab - 1.31M 1.32M 0.28M 0.39M
Total stockholder equity - 2.35M 7.08M 12.16M 15.33M
Deferred long term liab - - - - 0.00M
Other current liab - 1.04M 1237437.00M - 0.17M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock - 0.00M 0.00M 0.00M 0.00M
Retained earnings - -34.24M -29.77M -20.22M -16.86M
Other liab - - - - 0.00M
Good will - - -152853.85M - -152853.85M
Other assets - 0.06M 0.15M - 0.00M
Cash - 2.85M 7.41M 12.19M 15.40M
Total current liabilities - 1.31M 1.29M 0.28M 0.39M
Current deferred revenue - - -1237437.00M - -
Net debt - -2.82M -7.33M -12.19M -15.40M
Short term debt - 0.03M 0.05M - 0.00M
Short long term debt - - - - 0.00M
Short long term debt total - 0.03M 0.08M - -
Other stockholder equity - 36.59M 36.85M 32.38M 32.19M
Property plant equipment - 0.06M 0.12M - 0.00M
Total current assets - 3.38M 7.98M 12.29M 15.57M
Long term investments - - - - 0.00M
Net tangible assets - 2.19M 6.93M 12.01M 15.17M
Short term investments - - - - 0.00M
Net receivables - 0.04M - - -
Long term debt - - - - 0.00M
Inventory - - - - 0.00M
Accounts payable - 0.23M 1.24M 0.28M 0.23M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income - - - -0.00M -0.00M
Additional paid in capital - - - - 0.00M
Common stock total equity - - - - 0.00M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - 0.00M
Treasury stock - - - - 0.00M
Accumulated amortization - - - - 0.00M
Non currrent assets other - 0.06M 0.15M 0.15M 0.15M
Deferred long term asset charges - - - - 0.00M
Non current assets total - 0.27M 0.42M 0.15M 0.15M
Capital lease obligations - 0.03M 0.08M - 0.00M
Long term debt total - - - - 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - 0.00M -0.05M 0.00M 0.00M
Change to liabilities - 0.04M 0.96M 0.06M 0.06M
Total cashflows from investing activities - - -0.05M -0.05M -0.05M
Net borrowings - - - - 0.00M
Total cash from financing activities - - - 0.00M 14.52M
Change to operating activities - 0.03M -0.34M -0.10M -0.19M
Net income - -4.47M -9.55M -3.36M -2.12M
Change in cash - -4.56M -4.77M -3.21M 12.49M
Begin period cash flow 2.85M 7.41M 12.19M 15.40M 2.91M
End period cash flow 2.85M 2.85M 7.41M 12.19M 15.40M
Total cash from operating activities - -4.56M -4.72M -3.21M -2.03M
Depreciation - 0.01M 0.02M 0.00M 0.00M
Other cashflows from investing activities - - -0.01M -0.01M -0.01M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables - - - - 0.00M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities - - -0.05M - 14.52M
Change to netincome - -0.17M 4.21M 0.19M 0.17M
Capital expenditures 0.00M 0.00M 0.04M 0.04M 0.04M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital - 0.07M 0.60M -0.05M -0.13M
Stock based compensation - -0.17M 4.21M 0.19M 0.17M
Other non cash items - 0.00M - - 0.06M
Free cash flow - -4.56M -4.76M -3.21M -2.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RCAR
RenovaCare Inc
-
-%
0.00 - - - 5.11 -1.94
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

RenovaCare Inc

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.

9375 East Shea Blvd, Scottsdale, AZ, United States, 85260

888 398 0202

1

Name Title Year Born
Mr. Harmel S. Rayat Pres, CEO, CFO, Interim Sec. & Chairman 1961
Dr. Robin A. Robinson Ph.D. Chairman of Scientific Advisory Board, VP & Chief Scientific Officer 1956
Mr. Justin Frere CPA, CPA, M.B.A., MBA Treasurer 1973
Mr. Alan L. Rubino Consultant 1955
Dr. Jo Ellen Schweinle M.D. Chief Medical Officer NA
Mr. Harmel S. Rayat President, CEO, CFO & Interim Secretary 1961
Mr. Justin Frere CPA, M.B.A. Treasurer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…